Curtis, Jeffrey R. http://orcid.org/0000-0002-8907-8976
McInnes, Iain B. http://orcid.org/0000-0002-6462-4280
Rahman, Proton http://orcid.org/0000-0002-4521-2029
Gladman, Dafna D. http://orcid.org/0000-0002-9074-0592
Peterson, Steven
Yang, Feifei
Adejoro, Oluwakayode
Kollmeier, Alexa P. http://orcid.org/0000-0002-2059-7866
Shiff, Natalie J. http://orcid.org/0000-0002-7410-9709
Han, Chenglong http://orcid.org/0000-0001-7175-7834
Shawi, May http://orcid.org/0000-0001-6005-3938
Tillett, William http://orcid.org/0000-0001-7531-4125
Mease, Philip J. http://orcid.org/0000-0002-6620-0457
Clinical trials referenced in this document:
Documents that mention this clinical trial
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies
https://doi.org/10.1136/rmdopen-2022-002195
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials
https://doi.org/10.1136/rmdopen-2021-001679
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis
https://doi.org/10.1007/s40744-024-00642-9
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis
https://doi.org/10.1007/s40264-023-01361-w
The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial
https://doi.org/10.1007/s12325-022-02269-0
Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
https://doi.org/10.1007/s40744-023-00592-8
Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)
https://doi.org/10.1007/s40744-022-00444-x
Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA
https://doi.org/10.1136/rmdopen-2022-002934
Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis
https://doi.org/10.1136/rmdopen-2022-002789
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
https://doi.org/10.1136/rmdopen-2023-003977
Funding for this research was provided by:
Janssen Global Services, LLC
Janssen Research and Development
Article History
Received: 27 October 2023
Accepted: 17 January 2024
First Online: 22 February 2024
Declarations
:
: Jeffrey R. Curtis received grant/research support from AbbVie, Amgen, Bristol Myers Squibb, CorEvitas, Eli Lilly, Janssen, Myriad, Novartis, Pfizer, Sanofi, and UCB; and consulting fees from AbbVie, Amgen, Bristol Myers Squibb, CorEvitas, Eli Lilly, Janssen, Myriad, Novartis, Pfizer, Sanofi, and UCB. Iain B. McInnes received consultant fees from AbbVie, Amgen, Astra Zeneca, Bristol Myers Squibb, Cabaletta, Compugen, Eli Lilly, Gilead, Glaxo Smith Kline, Janssen, Novartis, Pfizer, Roche, Sanofi, and UCB; grant/research support from Amgen, Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo Smith Kline, Janssen, Novartis, Roche, and UCB; and is a shareholder for Causeway Therapeutics and Evelo Compugen. Proton Rahman received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB; meeting attendance/travel support from Janssen; and research grants from Janssen and Novartis. Dafna D. Gladman received grant support from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB; and consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB. Steven Peterson, Oluwakayode Adejoro, and Chenglong Han are employees of Janssen Global Services, LLC, and own stock in Johnson & Johnson. Feifei Yang was an employee of Janssen Global Services, LLC, at the time this work was performed, and owns stock in Johnson & Johnson. Alexa P. Kollmeier and May Shawi are an employees of Janssen Research & Development, LLC, and own stock in Johnson & Johnson. Natalie J. Shiff is an employee of Janssen Scientific Affairs, LLC, and owns stock in AbbVie, Gilead, Iovance, Jazz Pharmaceuticals, Johnson & Johnson, Novavax, and Viatris. William Tillett received consultant fees from AbbVie, Amgen, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, Ono-Pharma, Pfizer, and UCB; grant/research support from AbbVie, Amgen, Eli Lilly, Janssen, Pfizer, and UCB; and speaker fees from AbbVie, Amgen, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB. Philip J. Mease has received research grants from AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, SUN Pharma, and UCB; consulting fees from AbbVie, Acelyrin, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Immagene, Janssen, Moonlake Pharma, Novartis, Pfizer, SUN Pharma, UCB, Ventyx, and Xinthera; and speaker fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB.
: This study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All patients provided written informed consent, and the protocol was approved by local institutional review boards or ethics committees at each site (for several United States sites, Sterling Institutional Review Board approval number: 5910C) (Supplementary Materials Table S1). All patients provided written informed consent.